To test this hypothesis, we used three different approaches: chemotherapy with cisplatin, the standard of care in advanced NSCLC patients; targeted therapy with trametinib, a MEK inhibitor downstream of KRAS; and the epigenetic drug vorinostat, a pan-HDAC inhibitor. Here, MAP2K7 is linked to non-small cell lung carcinoma.